Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical and Translational Allergy|January 27, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface diseaseRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
American Journal of Clinical Dermatology|September 19, 2025
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD RegistryAmy S Paller, Danielle Marcoux, Michele Ramien, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 9, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapyRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
European Journal of Pediatrics|December 8, 2022
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangiomaMireille M Hermans, André B Rietman, Renske Schappin, et al.
Acta Dermato-Venereologica|February 21, 2017
Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive DrugsFloor M Garritsen, Jorien van der Schaft, Juul M van den Reek, et al.
Acta Dermato-Venereologica|August 31, 2023
Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockersMireille M Hermans, Suzanne G M A Pasmans, Marlies De Graaf, et al.
Acta Dermato-Venereologica|May 4, 2022
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile HaemangiomaMireille M Hermans, Corstiaan C Breugem, Renske Schappin, et al.
Dermatology (Basel, Switzerland)|January 16, 2024
Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their ParentsMireille M Hermans, Renske Schappin, Peter C J de Laat, et al.
Pageof 6